CA1203176A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- CA1203176A CA1203176A CA000429095A CA429095A CA1203176A CA 1203176 A CA1203176 A CA 1203176A CA 000429095 A CA000429095 A CA 000429095A CA 429095 A CA429095 A CA 429095A CA 1203176 A CA1203176 A CA 1203176A
- Authority
- CA
- Canada
- Prior art keywords
- cellulose
- pharmaceutical composition
- salbutamol
- physiologically acceptable
- acceptable salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Abstract
A B S T R A C T
Title: PHARMACEUTICAL COMPOSITION
A pharmaceutical composition is described which contains as active ingredient the .beta.-stimulant salbutamol or one or more of its physiologically acceptable salts. The stability of aqueous formulations of the composition is improved by including a cellulose derivative which provide an optically transparent or opalescent colloidal dispersion. Preferred compositions are liquid formulations suitable for oral administration in which the cellulose derivative also serves as a thickening agent.
Title: PHARMACEUTICAL COMPOSITION
A pharmaceutical composition is described which contains as active ingredient the .beta.-stimulant salbutamol or one or more of its physiologically acceptable salts. The stability of aqueous formulations of the composition is improved by including a cellulose derivative which provide an optically transparent or opalescent colloidal dispersion. Preferred compositions are liquid formulations suitable for oral administration in which the cellulose derivative also serves as a thickening agent.
Description
7~
Title: P~ARMAC~UTIC~L COMPOSITIONS
The present invention relates to a pharmaceutical composition containing as active ingredient the ~-stimulant salbutamol.
Salbutamol [(~l-tert-butylaminomethyl)-~-hydroxy-m-xylene~ 3-diol)~ and its physiologically acceptable salts are described in British Patent Specification No. 1200886. In that specification there is reference to pharmaceutical compositions containing salbutamol and there is a description of solid and liquid preparations for oral and intravenous use.
Liquid preparations of salbutamol and/or a physiologically acceptable salt thereof are conveniently water based and for oral use the preparations contain sucrose or sorbitol which acts both as a sweetener and thickening agent.
Such pharmaceutical compositions have been successfully marketed. However, it is known that the presence of a substance such as sucrose, or sorbitol or glycerol in aqueous compositions of salbutamol or a physiologically acceptable salt thereof is associated with an accelerated deterioration in the stability of the salbutamol in the composition.
We have now surprisingly found that the stability 03~7i of salbutamol in aqueous formulations may he significantly enhanced by the presence of a cellulose derivative which forms a colloidal dispersion in water.
Thus, the present invention provides an improved pharmaceutical composition which comprises an aqueous dispersion of one or more cellulose derivatives containing salbutamol and/or one or more of its physiologically acceptable salts.
According to a preferred embodiment of the invention, the pharmaceutical composition is formulated as a liquid preparation suitab]e for oral administration in which the cellulose derivative is advantageously used as thickening agent.
Suitable cellulose derivatives are those which form an optically transparent or opalescent dispersion in water, preferably an optically transparent colloidal dispersion.
Preferred cellulose derivatives include non-ionic derivatives such as alkyl and/or hydroxyalkyl ethers of cellulose, particularly Cl 4 alkyl and/or hydroxy Cl 4 alkylethers of cellulose for example, e~hyl cellulose, methyl cellulose, ethylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose and hydroxyethyl ethylcellulose.
3L2~3~L'76 Suitable ionic cellulose derivatives include carboxymethylceullose and salts thereof such as the calcium or sodium salts.
Particularly preferred cellulose derivatives S are hydroxyethyl cellulose and more especially hydroxypropyl methylceullose.
A preferred salt of salbutamol for use in the pharmaceutical composition according to the invention is the sulphate.
The total amount of dispersible cellulose derivatives present in the pharmaceutical composition accordin~ to the invention is such that the resulting colloidal dispersion has the desired enhanced stability and has a viscosity suitable for its proposed mode of administration. Preferably, the pharmaceutical composition contains at least 0.1~ w/v of the cellulose derivatives.
~or liquid preparations suitable for oral administration the total amount of cellulose derivatives will be determined primarily by the requirement to obtain a solution with a viscosity suitable for oral administration, preferably within the range 5 to lO,000 centipoises~ more preferably from 10 to 100 centipoises.
The concen'tration of the salhutamol or its salts in the formulation may be adjusted to suit the use ~2g33~
for which the form~lation is required and/or the patient's requirements. For example, for oral use the concentration is conveniently equivalent to lmg to 4mg, preferably 2mg, of salbutamol, expressed as salbutamol free base, per 5 ml of the liquid.
Preferably the pH of the pharmaceutical composition is in the range of from 2.5 to 7, more particularly 3.5 and this is conveniently achieved by the use of a buffer. For oral compositions, suitable buffers include a sodium citrate/citric acid buffer.
The pharmaceutical composition according to the invention may also contain an antimicrobial preservative, such as benzoic acid or a salt thereof which generates the acid in situ, or a methyl, ethyl, propyl or butyl hydroxybenzoate. For oral use the composition preferably also contains a flavouring;
a sweetening agent such as saccharin sodium or sodium cyclamate and~or a colouring.
The pharmaceutical composition according to the invention may be prepared by disperslng one or more cellulose derivatives in water, and then adding or mixing with the salbu~amol or physiologically acceptable salts thereof, conveniently dissolved in water,together with any optional components of the composition.
~Z~:~3~71E;
~5-Illustrative examples of formulations ~expressed as a 5 ml dose for oral administration according to the invention are as follows:-Example 1 5 Salbutamol sulphate 2.40 mg Hydroxyethyl cellulose ~Natrosol*250H) 22.5 mg Distilled water to 5 ml To prepare the formulation the hydroxyethyl~0 cellulos~ is dispersed in water and then mixed with a solution of salbutamol sulphate in water.
Example 2 Salbutamol sulphate 2~40 mg Sodium citrate dihydrate 9.60 mg Citxic aoid monohydrate 15.15 mg Natrosol 250H 15.0 mg Distilled water to 5.0 ml To prepare the formulation the hydroxyethyl cellulose is dispersed in water, and then mixed with a solution of salbutamol and the buf~ers salts in water.
* Trade Mark ~Z~3~76 Example 3 Salbutamol sulphate2.40 mg Sodium citrate dihydxate9.60 mg Citric acid monohydrate15.25 mg Hydroxypropyl methylcellulose viscosity type 400022.5 mg Distilled water to 5 ml Example 4 Salbutamol sulphate B.P.2.40 mg Sodium citrate B.P.7.5 mg Citric acid monohydrate ~.P. 25.0 mg Hydroxypropyl methylcellulose (viscosity type 4000)22.5 mq Sodium benzoate B.P.10.0 mg 15 Saccharin sodium B.P.2.5 mg Flavouring qS
Purified water to 5 ml To prepare the formulations of ~xamples 3 and 4 the hydroxypropyl methylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the salbutamol sulphate and the other components of the ~ormu].ation.
Title: P~ARMAC~UTIC~L COMPOSITIONS
The present invention relates to a pharmaceutical composition containing as active ingredient the ~-stimulant salbutamol.
Salbutamol [(~l-tert-butylaminomethyl)-~-hydroxy-m-xylene~ 3-diol)~ and its physiologically acceptable salts are described in British Patent Specification No. 1200886. In that specification there is reference to pharmaceutical compositions containing salbutamol and there is a description of solid and liquid preparations for oral and intravenous use.
Liquid preparations of salbutamol and/or a physiologically acceptable salt thereof are conveniently water based and for oral use the preparations contain sucrose or sorbitol which acts both as a sweetener and thickening agent.
Such pharmaceutical compositions have been successfully marketed. However, it is known that the presence of a substance such as sucrose, or sorbitol or glycerol in aqueous compositions of salbutamol or a physiologically acceptable salt thereof is associated with an accelerated deterioration in the stability of the salbutamol in the composition.
We have now surprisingly found that the stability 03~7i of salbutamol in aqueous formulations may he significantly enhanced by the presence of a cellulose derivative which forms a colloidal dispersion in water.
Thus, the present invention provides an improved pharmaceutical composition which comprises an aqueous dispersion of one or more cellulose derivatives containing salbutamol and/or one or more of its physiologically acceptable salts.
According to a preferred embodiment of the invention, the pharmaceutical composition is formulated as a liquid preparation suitab]e for oral administration in which the cellulose derivative is advantageously used as thickening agent.
Suitable cellulose derivatives are those which form an optically transparent or opalescent dispersion in water, preferably an optically transparent colloidal dispersion.
Preferred cellulose derivatives include non-ionic derivatives such as alkyl and/or hydroxyalkyl ethers of cellulose, particularly Cl 4 alkyl and/or hydroxy Cl 4 alkylethers of cellulose for example, e~hyl cellulose, methyl cellulose, ethylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose and hydroxyethyl ethylcellulose.
3L2~3~L'76 Suitable ionic cellulose derivatives include carboxymethylceullose and salts thereof such as the calcium or sodium salts.
Particularly preferred cellulose derivatives S are hydroxyethyl cellulose and more especially hydroxypropyl methylceullose.
A preferred salt of salbutamol for use in the pharmaceutical composition according to the invention is the sulphate.
The total amount of dispersible cellulose derivatives present in the pharmaceutical composition accordin~ to the invention is such that the resulting colloidal dispersion has the desired enhanced stability and has a viscosity suitable for its proposed mode of administration. Preferably, the pharmaceutical composition contains at least 0.1~ w/v of the cellulose derivatives.
~or liquid preparations suitable for oral administration the total amount of cellulose derivatives will be determined primarily by the requirement to obtain a solution with a viscosity suitable for oral administration, preferably within the range 5 to lO,000 centipoises~ more preferably from 10 to 100 centipoises.
The concen'tration of the salhutamol or its salts in the formulation may be adjusted to suit the use ~2g33~
for which the form~lation is required and/or the patient's requirements. For example, for oral use the concentration is conveniently equivalent to lmg to 4mg, preferably 2mg, of salbutamol, expressed as salbutamol free base, per 5 ml of the liquid.
Preferably the pH of the pharmaceutical composition is in the range of from 2.5 to 7, more particularly 3.5 and this is conveniently achieved by the use of a buffer. For oral compositions, suitable buffers include a sodium citrate/citric acid buffer.
The pharmaceutical composition according to the invention may also contain an antimicrobial preservative, such as benzoic acid or a salt thereof which generates the acid in situ, or a methyl, ethyl, propyl or butyl hydroxybenzoate. For oral use the composition preferably also contains a flavouring;
a sweetening agent such as saccharin sodium or sodium cyclamate and~or a colouring.
The pharmaceutical composition according to the invention may be prepared by disperslng one or more cellulose derivatives in water, and then adding or mixing with the salbu~amol or physiologically acceptable salts thereof, conveniently dissolved in water,together with any optional components of the composition.
~Z~:~3~71E;
~5-Illustrative examples of formulations ~expressed as a 5 ml dose for oral administration according to the invention are as follows:-Example 1 5 Salbutamol sulphate 2.40 mg Hydroxyethyl cellulose ~Natrosol*250H) 22.5 mg Distilled water to 5 ml To prepare the formulation the hydroxyethyl~0 cellulos~ is dispersed in water and then mixed with a solution of salbutamol sulphate in water.
Example 2 Salbutamol sulphate 2~40 mg Sodium citrate dihydrate 9.60 mg Citxic aoid monohydrate 15.15 mg Natrosol 250H 15.0 mg Distilled water to 5.0 ml To prepare the formulation the hydroxyethyl cellulose is dispersed in water, and then mixed with a solution of salbutamol and the buf~ers salts in water.
* Trade Mark ~Z~3~76 Example 3 Salbutamol sulphate2.40 mg Sodium citrate dihydxate9.60 mg Citric acid monohydrate15.25 mg Hydroxypropyl methylcellulose viscosity type 400022.5 mg Distilled water to 5 ml Example 4 Salbutamol sulphate B.P.2.40 mg Sodium citrate B.P.7.5 mg Citric acid monohydrate ~.P. 25.0 mg Hydroxypropyl methylcellulose (viscosity type 4000)22.5 mq Sodium benzoate B.P.10.0 mg 15 Saccharin sodium B.P.2.5 mg Flavouring qS
Purified water to 5 ml To prepare the formulations of ~xamples 3 and 4 the hydroxypropyl methylcellulose is dispersed in hot water, cooled and then mixed with an aqueous solution containing the salbutamol sulphate and the other components of the ~ormu].ation.
Claims (25)
1. A pharmaceutical composition comprising an aqueous dispersion of one or more cellulose derivatives containing salbutamol and/or one or more of its physiologically acceptable salts.
2. A pharmaceutical composition according to claim 1, which comprises the one or more cellulose derivatives in a total amount of at least 0.1% w/v.
3. A pharmaceutical composition according to claim 1 or 2, wherein the cellulose derivative is an alkyl and/or hydroxyalkyl ether.
4. A pharmaceutical composition according to any of claims 1 or 2, in which the cellulose derivative is selected from ethyl cellulose, methyl cellulose, ethyl-methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl-cellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose,carboxymethylcellulose and salts of carboxymethylcellulose.
5. A pharmaceutical composition according to claim 1 or 2, wherein the cellulose derivative is hydroxypropyl methylcellulose.
6. A pharmaceutical composition according to claim 1, which is formulated as a liquid preparation suitable for oral administration.
7. A pharmaceutical composition according to claim 6, which contains the one or more cellulose derivatives in a total amount such as to provide the liquid preparation with a viscosity in the range of from 5 to 10,000 centipoises.
8. A pharmaceutical composition according to claim 7, wherein the viscosity is in the range of from 10 to 100 centipoises.
9. A pharmaceutical composition according to any of claims 6 to 8, which contains salbutamol and/or one or more of its physiologically acceptable salts in a concentration of 1 mg to 4 mg, expressed as salbutamol free base per 5 ml of liquid.
10. A pharmaceutical composition according to claims 6 to 8 which contains salbutamol and/or one or more of its physiologically acceptable salts in a concentration of 2 mg, expressed as salbutamol free base per 5 ml of liquid.
11. A pharmaceutical composition according to claim 1 or 2, having a pH of 3.5.
12. A pharmaceutical composition according to claim 6, 7 or 8, having a pH of 73.5.
13. A method of preparing an aqueous based pharm-aceutical composition comprising salbutamol and/or one or more of its physiologically acceptable salts wherein the salbutamol and/or one or more of its physiologically acceptable salts has improved stability, which methods comprises mixing one or more cellulose derivatives with salbutamol and/or one or more of its physiologically acceptable salts in the presence of water and introducing before, during or after mixing any optional components of the composition.
14. A method of improving the stability of salbut-amol and/or its physiologically acceptable salts in an aqueous based pharmaceutical composition containing as active ingredient salbutamol and/or one or more of its physiologically acceptable salts which method comprises mixing one or more cellulose derivatives with salbutamol and/or one or more of its physiologically acceptable salts in the presence of water and introducing before, during or after mixing any optional components of the composition.
15. A method according to claim 13 or 14 wherein the one or more cellulose derivatives are dispersed in water and then mixed with salbutamol and/or one or more of its physiologically acceptable salts.
16. A method according to claim 13 or 14 which comprises selecting the amount of cellulose derivative such that the resulting pharmaceutical composition contains the one or more cellulose derivatives in a total amount of at least 0.1% w/v.
17. A method according to claim 13 or 14 wherein the cellulose derivative is an alkyl and/or hydroxyalkyl
18. A method according to claim 13 or 14 in which the cellulose derivative is selected from ethyl cellulose, methyl cellulose, ethylmethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl-cellulose, hydroxyethyl ethylcellulose, carboxymethyl-cellulose and salts of carboxymethylcellulose.
19. A method according to claim 13 or 14 wherein the cellulose derivative is hydroxypropyl methylcellulose.
20. A method according to claim 13 which comprises formulating the resulting pharmaceutical composition as a liquid preparation suitable for oral administration containing the one or more cellulose derivatives in a total amount such as to provide the liquid preparation with a viscosity in the range of from 5 to 10,000 centipoises.
21. A method according to claim 20 wherein the viscosity is in the range of from 10 to 100 centipoises.
22. A method according to claim 20 which comprises selecting the amount of salbutamol or physiologically acceptable salts such that the resulting pharmaceutical composition contains salbutamol and/or one or more of its physiologically acceptable salts in a concentration of 1 mg to 4 mg, expressed as salbutamol free base per 5 ml of liquid.
23. A method according to claim 22 wherein the concentration is 2 mg expressed as salbutamol free base per 5 ml of liquid.
24. A method according to claim 13, 14 or 20 which comprises controlling the pH such that the resulting pharmaceutical composition has a pH of 3.5.
25. A method according to claim 21, 22 or 23 which comprises controlling the pH such that the result-ing pharmaceutical composition has a pH of 3.5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8215502 | 1982-05-27 | ||
| GB8215502 | 1982-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1203176A true CA1203176A (en) | 1986-04-15 |
Family
ID=10530673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000429095A Expired CA1203176A (en) | 1982-05-27 | 1983-05-27 | Pharmaceutical compositions |
Country Status (25)
| Country | Link |
|---|---|
| JP (1) | JPH0629181B2 (en) |
| AT (1) | AT390191B (en) |
| AU (1) | AU567675B2 (en) |
| BE (1) | BE896870A (en) |
| CA (1) | CA1203176A (en) |
| CH (1) | CH656308A5 (en) |
| DE (1) | DE3319356C2 (en) |
| DK (1) | DK167558B1 (en) |
| ES (1) | ES8502336A1 (en) |
| FI (1) | FI81257C (en) |
| FR (1) | FR2527442B1 (en) |
| GR (1) | GR82681B (en) |
| IE (1) | IE55139B1 (en) |
| IL (1) | IL68805A0 (en) |
| IT (1) | IT1174759B (en) |
| LU (1) | LU84828A1 (en) |
| MY (1) | MY8700275A (en) |
| NL (1) | NL192663C (en) |
| NO (1) | NO163166C (en) |
| NZ (1) | NZ204385A (en) |
| PH (1) | PH19601A (en) |
| PT (1) | PT76773B (en) |
| SE (1) | SE454946B (en) |
| ZA (1) | ZA833854B (en) |
| ZW (1) | ZW11883A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624213A (en) * | 1963-10-30 | 1971-11-30 | Merck & Co Inc | Method of sterilizing aqueous pharmaceutical solutions employing propylene oxide and entrained air |
| GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| GB1453034A (en) * | 1972-12-15 | 1976-10-20 | Boehringer Sohn Ingelheim | Pharmaceutical composition for treating spasticity |
| JPS5831210B2 (en) * | 1973-04-09 | 1983-07-05 | 武田薬品工業株式会社 | antennae |
| DE2714065A1 (en) * | 1977-03-30 | 1978-10-12 | Boehringer Mannheim Gmbh | INSTILLATION PREPARATION |
-
1983
- 1983-05-20 CH CH2779/83A patent/CH656308A5/en not_active IP Right Cessation
- 1983-05-24 GR GR71454A patent/GR82681B/el unknown
- 1983-05-26 FR FR8308722A patent/FR2527442B1/en not_active Expired
- 1983-05-26 NO NO831875A patent/NO163166C/en not_active IP Right Cessation
- 1983-05-27 IT IT48384/83A patent/IT1174759B/en active Protection Beyond IP Right Term
- 1983-05-27 FI FI831893A patent/FI81257C/en not_active IP Right Cessation
- 1983-05-27 DE DE3319356A patent/DE3319356C2/en not_active Expired - Lifetime
- 1983-05-27 NZ NZ204385A patent/NZ204385A/en unknown
- 1983-05-27 ES ES522752A patent/ES8502336A1/en not_active Expired
- 1983-05-27 PH PH28974A patent/PH19601A/en unknown
- 1983-05-27 DK DK241783A patent/DK167558B1/en not_active IP Right Cessation
- 1983-05-27 AT AT0195283A patent/AT390191B/en not_active IP Right Cessation
- 1983-05-27 IE IE1267/83A patent/IE55139B1/en not_active IP Right Cessation
- 1983-05-27 LU LU84828A patent/LU84828A1/en unknown
- 1983-05-27 ZA ZA833854A patent/ZA833854B/en unknown
- 1983-05-27 SE SE8303012A patent/SE454946B/en not_active IP Right Cessation
- 1983-05-27 CA CA000429095A patent/CA1203176A/en not_active Expired
- 1983-05-27 JP JP58093896A patent/JPH0629181B2/en not_active Expired - Lifetime
- 1983-05-27 NL NL8301900A patent/NL192663C/en not_active IP Right Cessation
- 1983-05-27 IL IL68805A patent/IL68805A0/en not_active IP Right Cessation
- 1983-05-27 PT PT76773A patent/PT76773B/en unknown
- 1983-05-27 ZW ZW118/83A patent/ZW11883A1/en unknown
- 1983-05-27 AU AU15039/83A patent/AU567675B2/en not_active Expired
- 1983-05-27 BE BE0/210866A patent/BE896870A/en not_active IP Right Cessation
-
1987
- 1987-12-30 MY MY275/87A patent/MY8700275A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5024997A (en) | Palatable ibuprofen solutions | |
| US4499108A (en) | Stable pleasant-tasting albuterol sulfate pharmaceutical formulations | |
| US5498426A (en) | Liquid antacid compositions | |
| US5182101A (en) | Anti-plaque toothpaste | |
| MXPA97002456A (en) | Liquid antiacidal compositions containing calcium carbonate and possibly simeticone as active compounds and monobasic potassium phosphate and potassium bicarbonate as regula | |
| JP2590156B2 (en) | Pharmaceutical composition for oral administration | |
| US4594359A (en) | Pharmaceutical compositions | |
| CA1326453C (en) | Pharmaceutical composition containing pentamidine | |
| JP2002179541A (en) | Composition for oral cavity containing cationic disinfectant | |
| CA1203176A (en) | Pharmaceutical compositions | |
| JPS6351341A (en) | Azulene-containing liquid formulation | |
| KR20120078754A (en) | Oral pharmaceutical solutions containing telbivudine | |
| GB2120942A (en) | Salbutamol compositions | |
| EP0468232B1 (en) | Suspending syrups | |
| EP1603550A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid | |
| JPH1029937A (en) | Pharmaceutical preparation of mefenamic acid aqueous solution | |
| JP3136421B2 (en) | Cetylpyridinium stabilizer | |
| HUT63060A (en) | Process for producing pharmaceutical compositions locally applicable on nose and eye, comprising bradykinin antagonists | |
| US4666926A (en) | Transdermal formulations | |
| US5879711A (en) | Stable antiandrogenic gel composition | |
| JP2893807B2 (en) | Azulene derivative-containing solution | |
| JPH01313430A (en) | Water-soluble preparation of coccidium inhibitor | |
| WO2022064006A1 (en) | Hydroxyapatite composition for treatment and/or prevention of a virus infection | |
| JPS6348211A (en) | Azulene-containing composition | |
| JPS647967B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |